Mixed-type autoimmune hemolytic anemia
Learn about Mixed-type autoimmune hemolytic anemia, its reported features, relevant specialists, and questions to discuss at a medical consultation.
Also known as: Mixed AIHA
The sources compiled here do not cover: diagnosis, treatment, prevention, prognosis, prevalence. Ask the treating doctor about these.
What it is
From: Orphanet
Mixed autoimmune hemolytic anemia is a type of autoimmune hemolytic anemia (AIHA) defined by the presence of both warm and cold autoantibodies, which have a deleterious effect on red blood cells at either body temperature or at lower temperatures.
Reported clinical features and what the terms mean
The following findings are associated with this condition in Orphanet. They are not a checklist for diagnosing yourself, and they do not all occur in every affected person. Some are examination, imaging or laboratory findings that cannot be recognised at home.
The frequency labels describe how often a finding was reported among people with the condition in the source. They do not give the chance that a person with that symptom has the condition. Definitions below reproduce HPO terminology; they explain the term, not the likely severity in an individual.
- Autoimmune hemolytic anemia · Very frequent (99-80%)
- An autoimmune form of hemolytic anemia.
- Autoimmunity · Very frequent (99-80%)
- The occurrence of an immune reaction against the organism's own cells or tissues.
- Exertional dyspnea · Very frequent (99-80%)
- Perceived difficulty to breathe that occurs with exercise or exertion and improves with rest.
- Fatigue · Very frequent (99-80%)
- A subjective feeling of tiredness characterized by a lack of energy and motivation.
- Muscle weakness · Very frequent (99-80%)
- Reduced strength of muscles.
- Pallor · Very frequent (99-80%)
- Abnormally pale skin.
- Arthralgia · Frequent (79-30%)
- Joint pain.
- Lymphoma · Frequent (79-30%)
- A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells.
- Skin rash · Frequent (79-30%)
- A red eruption of the skin.
- Systemic lupus erythematosus · Frequent (79-30%)
- A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes.
- Abnormal urinary color · Occasional (29-5%)
- An abnormal color of the urine, that is, the color of the urine appears different from the usual straw-yellow color.
- Fever · Occasional (29-5%)
- Body temperature elevated above the normal range.
- Increased total bilirubin · Occasional (29-5%)
- Increased concentration of total (conjugated and unconjugated) bilirubin in the blood.
- Tachycardia · Occasional (29-5%)
- A rapid heartrate that exceeds the range of the normal resting heartrate for age.
When it may begin
From: Orphanet
All ages
Inheritance in the source
From: Orphanet
Multigenic/multifactorial
Which doctor should you see?
The suggested department for discussing Mixed-type autoimmune hemolytic anemia is Haematology, with a haematologist as the relevant type of clinician. General physician / Family Medicine; paediatrician for children. Referral depends on symptoms.
This is an editorial referral starting point. The appropriate clinic depends on the person’s age, symptoms, previous diagnosis and local services. The first clinician can decide whether another specialty or a team is needed; a department label does not confirm the diagnosis.
How to prepare for an assessment
Bring a short timeline of the main symptoms: when they first appeared, whether they are constant or episodic, what seems to change them, and how they affect daily activities. Include previous reports, discharge summaries, current medicines and supplements, allergies, and any relevant family history. A dated record is more useful than trying to match every feature in an online article.
Ask the clinician what is already established and what remains uncertain. If a test is suggested, ask what question it answers, what its limitations are and how the result would change the next step. The information here is not an instruction to arrange every possible test. In children, bring growth, developmental and school information if it is relevant to the concern.
- Which blood-cell, marrow, bleeding or clotting finding matters most?
- Does the diagnosis need confirmation or a more precise subtype?
- Which symptoms or laboratory changes should trigger earlier review?
Treatment discussions and follow-up
The material gathered for this draft does not provide a complete condition-specific treatment pathway for Mixed-type autoimmune hemolytic anemia. That gap does not mean that treatment is unavailable. A clinician needs to establish the diagnosis and review current guidance before recommending medicines, procedures, rehabilitation or other support.
Before leaving the appointment, clarify the next review date, who will communicate results, and whom to contact if the situation changes. Discuss difficulties with sleep, work, school, mobility, eating or emotional wellbeing when these are relevant. Practical support may require coordination between the treating clinician and other services.
The collected references do not establish a complete prevention or long-term outlook section for this entry. Missing information should not be interpreted as proof that prevention is impossible or that a particular outcome is inevitable. Ask what is known for the exact subtype, stage and personal circumstances, and which uncertainties remain.
When to seek emergency help
Severe breathing difficulty, collapse, new stroke-like symptoms, a seizure that is prolonged or repeated without recovery, uncontrolled major bleeding, or an immediate risk of self-harm require emergency help. In India, call 112 or reach the nearest emergency department. This is a general, non-exhaustive warning list; it is not a condition-specific triage tool.
This condition is usually assessed by a haematologist. Every profile shows the doctor’s registration and what has been checked.
Sources
- Orphanet — Mixed-type autoimmune hemolytic anemia — Orphadata Science, CC BY 4.0
- Human Phenotype Ontology Consortium — terminology definitions — HPO licence; definitions reproduced without alteration
- Government of India — Emergency Response Support System — Official reference for India emergency number
Source: MedlinePlus, National Library of Medicine. Orphadata Science: Free access data from Orphanet. © INSERM 1999; July 2026 data, CC BY 4.0. This product uses the Human Phenotype Ontology (hp/releases/2026-09-01). Only sources listed for this article apply. Source material has been selected and arranged; HPO definitions are reproduced without alteration. No source organisation endorses this compilation. Köhler S et al. The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data. Nucleic Acids Research 2014;42(D1):D966–D974. doi:10.1093/nar/gkt1026.
General information, not advice about your situation. Errors can be reported through the corrections process. Reference TDI-C-1575.